The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Open accessAbstract
Knowledge of “actionable” somatic genomic alterations present in each tumor (e.g., point mutations, small insertions/deletions, and copy-number alterations that direct therapeutic options) should facilitate individualized approaches to cancer treatment. However, clinical implementation of systematic genomic profiling has rarely been achieved beyond limited numbers of oncogene point mutations. To address this challenge, we utilized a targeted, massively parallel sequencing approach to detect tumor genomic alterations in formalin-fixed, paraffin-embedded (FFPE) tumor samples. Nearly 400-fold mean sequence coverage was achieved, and single-nucleotide sequence variants, small insertions/deletions, and chromosomal copynumber alterations were detected simultaneously with high accuracy compared with other methods in clinical use. Putatively actionable genomic alterations, including those that predict sensitivity or resistance to established and experimental therapies, were detected in each tumor sample tested. Thus, targeted deep sequencing of clinical tumor material may enable mutation-driven clinical trials and, ultimately, “personalized” cancer treatment. Significance: Despite the rapid proliferation of targeted therapeutic agents, systematic methods to profile clinically relevant tumor genomic alterations remain underdeveloped. We describe a sequencing-based approach to identifying genomic alterations in FFPE tumor samples. These studies affirm the feasibility and clinical utility of targeted sequencing in the oncology arena and provide a foundation for genomics-based stratification of cancer patients. Cancer Discovery; 2(1); 82–93. ©2011 AACR. Read the Commentary on this article by Corless and Spellman, p. 23 This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Self-citationInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 5×
“The BATTLE Trial: Personalizing Therapy for Lung Cancer”
MethodInfluentialDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationGnirke, A., Melnikov, A., Maguire, J., Rogov, P., LeProust, E. M., Brockman, W., Fennell, T., Giannoukos, G., Fisher, S., Russ, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1523 · Cited by 1,433
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156
Advances in understanding cancer genomes through second-generation sequencing
Meyerson, M., Gabriel, S., & Getz, G. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2841 · Cited by 1,116
Self-citationDissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
Self-citationHigh-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988
Self-citationMolecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Carrier testing for severe childhood recessive diseases by next-generation sequencing
Bell, C. J., Dinwiddie, D. L., Miller, N. A., Hateley, S. L., Ganusova, E. E., Mudge, J., Langley, R. J., Zhang, L., Lee, C. C., Schilkey, F. D., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001756 · Cited by 706
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Paik, P. K., Arcila, M. E., Fara, M., Sima, C. S., Miller, V. A., Kris, M. G., Ladanyi, M., & Riely, G. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1280 · Cited by 691
Fisher, S., Barry, A., Abreu, J., Minie, B., Nolan, J., Delorey, T. M., Young, G., Fennell, T. J., Allen, A., Ambrogio, L., et al. (2011) · Genome Biology · doi:10.1186/gb-2011-12-1-r1 · Cited by 682
Self-citationLara, P. N., Natale, R., Crowley, J., Lenz, H. J., Redman, M. W., Carleton, J. E., Jett, J., Langer, C. J., Kuebler, J. P., Dakhil, S. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1061 · Cited by 525
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007887 · Cited by 438
Self-citationWagner, A. J., Malinowska-Kolodziej, I., Morgan, J. A., Qin, W., Fletcher, C. D. M., Vena, N., Ligon, A. H., Antonescu, C. R., Ramaiya, N. H., Demetri, G. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2981 · Cited by 399
Dias‐Santagata, D., Akhavanfard, S., David, S. S., Vernovsky, K., Kuhlmann, G., Boisvert, S. L., Stubbs, H., McDermott, U., Settleman, J., Kwak, E. L., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000070 · Cited by 396
Comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing
Shearer, A. E., DeLuca, A. P., Hildebrand, M. S., Taylor, K. R., Gurrola, J., Scherer, S., Scheetz, T. E., & Smith, R. J. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012989107 · Cited by 340
Identification of genetic variants using bar-coded multiplexed sequencing
Craig, D. W., Pearson, J. V., Szelinger, S., Sekar, A., Redman, M., Corneveaux, J. J., Pawlowski, T. L., Laub, T., Nunn, G., Stephan, D. A., et al. (2008) · Nature Methods · doi:10.1038/nmeth.1251 · Cited by 300
Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., Martini, M., Cipani, T., Marrapese, G., Mazzucchelli, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007287 · Cited by 259
Clinical Implications of the Cancer Genome
MacConaill, L. E., & Garraway, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4944 · Cited by 229
Self-citationCRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
Smalley, K. S. M., Xiao, M., Villanueva, J., Nguyen, T. K., Flaherty, K. T., Letrero, R., Van Belle, P., Elder, D. E., Wang, Y., Nathanson, K. L., et al. (2009) · Oncogene · doi:10.1038/onc.2008.362 · Cited by 216
Systematic comparison of three genomic enrichment methods for massively parallel DNA sequencing
Teer, J. K., Bonnycastle, L. L., Chines, P. S., Hansen, N. F., Aoyama, N., Swift, A. J., Abaan, H. O., Albert, T. J., Program, N. C. S., Margulies, E. H., et al. (2010) · Genome Research · doi:10.1101/gr.106716.110 · Cited by 206
Targeted Next-Generation Sequencing for the Molecular Genetic Diagnostics of Cardiomyopathies
Meder, B., Haas, J., Keller, A., Heid, C., Just, S., Borries, A., Boisguerin, V., Scharfenberger-Schmeer, M., Stähler;, P., Beier, M., et al. (2011) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.110.958322 · Cited by 177
Hodges, E., Rooks, M., Xuan, Z., Bhattacharjee, A., Benjamin Gordon, D., Brizuela, L., Richard McCombie, W., & Hannon, G. J. (2009) · Nature Protocols · doi:10.1038/nprot.2009.68 · Cited by 177
Bostner, J., Ahnström Waltersson, M., Fornander, T., Skoog, L., Nordenskjöld, B., & Stål, O. (2007) · Oncogene · doi:10.1038/sj.onc.1210506 · Cited by 172
Boige, V., Mendiboure, J., Pignon, J.-P., Loriot, M.-A., Castaing, M., Barrois, M., Malka, D., Trégouët, D.-A., Bouché, O., Le Corre, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2106 · Cited by 172
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z. Y., Wang, B., Shao, Z., Wang, Z., & Hu, X. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-248 · Cited by 162
Detection of KRAS and BRAF Mutations in Colorectal Carcinoma
Arcila, M. E., Lau, C., Nafa, K., & Ladanyi, M. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.005 · Cited by 148
Xie, W. Q., Rimm, D. L., Lin, Y., Shih, W. J., & Reiß, M. (2003) · The Cancer Journal · doi:10.1097/00130404-200307000-00013 · Cited by 121
Brevet, M., Johnson, M. L., Azzoli, C. G., & Ladanyi, M. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.10.014 · Cited by 120
Liao, G. J. W., Lun, F. M. F., Zheng, Y. W. L., Chan, K. C. A., Leung, T. Y., Lau, T. K., Chiu, R. W. K., & Lo, Y. D. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.154336 · Cited by 120
Roy, P. G., Pratt, N. R., Purdie, C. A., Baker, L., Ashfield, A., Quinlan, P., & Thompson, A. M. (2009) · International Journal of Cancer · doi:10.1002/ijc.25034 · Cited by 94
Zang, Z. J., Ong, C. K., Cutcutache, I., Yu, W., Zhang, S. L., Huang, D., Ler, L. D., Dykema, K. J., Gan, A., Tao, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1749 · Cited by 91
Multiplex Mutation Screening by Mass Spectrometry
Beadling, C., Heinrich, M. C., Warrick, A., Forbes, E. M., Nelson, D., Justusson, E., Levine, J., Neff, T. L., Patterson, J., Presnell, A., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.04.003 · Cited by 85
Lundgren, K., Holm, K., Nordenskjöld, B. A., Borg, Å., & Landberg, G. (2008) · Breast Cancer Research · doi:10.1186/bcr2150 · Cited by 80
Targeted resequencing of candidate genes using selector probes
Johansson, H., Isaksson, M., Falk-Sörqvist, E., Roos, F., Stenberg, J., Sjöblom, T., Botling, J., Micke, P., Edlund, K., Fredriksson, S., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1005 · Cited by 78
Mutation discovery by targeted genomic enrichment of multiplexed barcoded samples
Nijman, I. J., Mokrý, M., van Boxtel, R., Toonen, P. W., de Bruijn, E., & Cuppen, E. P. J. G. (2010) · Nature Methods · doi:10.1038/nmeth.1516 · Cited by 67
Berg, J. S., Evans, J. P., Leigh, M. W., Omran, H., Bizon, C., Mane, K. K., Knowles, M. R., Weck, K. E., & Zariwala, M. A. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e318203cff2 · Cited by 64
Targeted Exon Sequencing by In‐Solution Hybrid Selection
Blumenstiel, B. S., Cibulskis, K., Fisher, S., DeFelice, M. T., Barry, A. J., Fennell, T. J., Abreu, J., Minie, B., Costello, M., Young, G., et al. (2010) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1804s66 · Cited by 62
Self-citationGroßmann, V., Kohlmann, A., Klein, H.-U., Schindela, S., Schnittger, S., Dicker, F., Dugas, M., Kern, W., Haferlach, T., & Haferlach, C. (2011) · Leukemia · doi:10.1038/leu.2010.309 · Cited by 47
Ogata, H., Sato, H., Takatsuka, J., & Luca, L. M. D. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00648-6 · Cited by 43
Chmielecki, J., Peifer, M., Jia, P., Socci, N. D., Hutchinson, K. E., Viale, A. J., Zhao, Z., Thomas, R. K., & Pao, W. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq579 · Cited by 40
Summerer, D., Schracke, N., Wu, H., Cheng, Y., Bau, S., Stähler, C., Stähler, P. F., & Beier, M. (2010) · Genomics · doi:10.1016/j.ygeno.2010.01.006 · Cited by 34
Kiialainen, A., Karlberg, O., Ahlford, A., Sigurðsson, S., Lindblad‐Toh, K., & Syvänen, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016486 · Cited by 31
Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors
Duffy, A. G., & Kummar, S. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0125-x · Cited by 22
Cited by
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
“55(0) 42(11) 20(32) 11(41) 6(44) 2(47) 0(49) 3(4) 0(6) 0(6) 0(6) 0(6) 0(6)”
Lessons from the Cancer Genome
Garraway, L. A., & Lander, E. S. (2013) · Cell · doi:10.1016/j.cell.2013.03.002 · Cited by 1,308
Self-citationForshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D. W. Y., Kaper, F., Dawson, S.-J., Piskorz, A. M., Jimenez-Linan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,297
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Self-citation
Metadata
- Authors
- Wagle, N., Berger, M. F., Davis, M. J., Blumenstiel, B., DeFelice, M., Pochanard, P., Ducar, M., Van Hummelen, P., MacConaill, L. E., Hahn, W. C., Meyerson, M., Gabriel, S. B., & Garraway, L. A.
- Venue
- Cancer Discovery
- Published
- 2012-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 82-93
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2130940380
- Cited by
- 533
- References
- 54
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.